EADV 2026视频特辑｜Anna López-Ferrer博士：超说明书用药与银屑病口服新药前景

Anna López-Ferrer博士长期深耕银屑病与银屑病关节炎领域，15年前便牵头设立联合门诊，推动两类患者的早期诊断。她介绍了靶向IL-4、IL-13与IL-31药物在特应性皮炎以外的超说明书应用，以及相关支持性证据和病例系列；还提及在争议专场中与同事探讨生物标志物能否预测银屑病患者对生物制剂的应答。此外，她还分享了本届大会上令她印象深刻的在研银屑病口服药物——这类药物尚未上市，但疗效有望与长期使用的生物制剂相当。

 

Dr. Anna López-Ferrer has long focused on psoriasis and psoriatic arthritis, and 15 years ago she set up a joint clinic to promote early diagnosis of both conditions. She outlines the off-label use of IL-4-, IL-13- and IL-31-targeted agents beyond atopic dermatitis, with supporting evidence and case series, and her controversies-session discussion with a colleague on whether biomarkers can predict biologic response in psoriasis. She also highlights the investigational oral psoriasis therapies that impressed her most at this year's congress — not yet on the market, but with efficacy potentially comparable to long-established biologics.